Healthcare Industry News: TYSABRI
News Release - June 18, 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and QualityPETALUMA, Calif.--(HSMN NewsFeed)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS ) today announced that it has appointed biotechnology and pharmaceutical industry veteran, Dana Redhair, to the position of vice president of regulatory affairs and quality. Mr. Redhair will direct the execution of the company's ongoing regulatory strategy with responsibility for all regulatory submissions of the company's product candidates.
Most recently he served as vice president of regulatory affairs and quality at SGX Pharmaceuticals (Nasdaq:SGXP ) where he facilitated a potential rolling NDA filing for Troxatyl(TM) (troxacitabine) for the treatment of patients with acute myeloid leukemia. Prior to that he was executive director of regulatory affairs at CancerVax Corporation where he oversaw two international Canvaxin(TM) Phase III clinical trials.
During his career, Mr. Redhair has also served in key regulatory affairs roles for Elan Pharmaceuticals, Chiron Corporation, Berlex Laboratories, Genenetch and the U.C.S.F. Cancer Research Institute. He received a bachelor of arts in history and science from Harvard University in 1981. His regulatory experience includes working on the following license applications:
- US approval of TYSABRI® (natalizumab), including regulatory US, EU and ROW filing strategies and execution for two indications.
- Betaseron® (interferon beta-1b) from IND stage to worldwide commercialization and label extension.
- REGRANEX® (becaplermin) 0.01% Gel from Phase II to US, EU and ROW approvals.
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating, oxychlorine compound that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Oculus' website is www.oculusis.com.
Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about our ability to obtain regulatory approvals in any specific time frame, if at all. These forward-looking statements are identified by the use of words such as "will," "expect," "announce," "planning," and "anticipated," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.
Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.
Source: Oculus Innovative Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.